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Abstract
 
Inflammation removes developing and mature lymphocytes from the bone marrow (BM) and
induces the appearance of developing B cells in the spleen. BM granulocyte numbers increase
after lymphocyte reductions to support a reactive granulocytosis. Here, we demonstrate that
inflammation, acting primarily through tumor necrosis factor 
 
 
 
 (TNF
 
 
 
), mobilizes BM lym-
phocytes. Mobilization reflects a reduced CXCL12 message and protein in BM and changes to
the BM environment that prevents homing by cells from naive donors. The effects of TNF
 
 
 
are potentiated by interleukin 1 
 
 
 
 (IL-1
 
 
 
), which acts primarily to expand the BM granulocyte
compartment. Our observations indicate that inflammation induces lymphocyte mobilization
by suppressing CXCL12 retention signals in BM, which, in turn, increases the ability of IL-1
 
 
 
to expand the BM granulocyte compartment. Consistent with this idea, lymphocyte mobilization
and a modest expansion of BM granulocyte numbers follow injections of pertussis toxin. We
propose that TNF
 
 
 
 and IL-1
 
 
 
 transiently specialize the BM to support acute granulocytic responses
and consequently promote extramedullary lymphopoiesis.
Key words: bone marrow • innate immunity • TNF
 
 
 
 • hematopoiesis • neutrophilia
 
Introduction
 
Severe infections in humans deplete BM lymphocytes and
induce the appearance of immature lymphocytes in the
blood (1, 2). In mice, analogous responses follow infections
(3) or administration of adjuvants (3, 4). Within a week of
immunization, significant numbers of T cells and both devel-
oping and mature B cells are lost from mouse BM, whereas
increases in granulocyte numbers and granulocytosis are
often observed (3).
The mechanisms whereby adjuvants/inflammation elicit
BM lymphopenia are not understood but are independent
of adaptive immunity (4). Could innate immune effectors
regulate BM lymphopoiesis? In vitro, IL-1 inhibits B lym-
phopoiesis and promotes myelopoiesis (5, 6). These effects
are reversible, and appear to reflect change in nonhemato-
poietic BM compartments (6). The early stages of B cell
development are exceptionally sensitive to apoptosis (7),
and the proinflammatory cytokine IFN
 
 
 
/
 
 
 
 can suppress B
lymphopoiesis by inducing cell death (8–10). However,
this suppression only occurs at pharmacologic doses (8),
and does not require signal transducer and activator of tran-
scription 1, the physiologic mediator of IFN signaling (11).
Alternatively, as inflammation elicits developing B lym-
phocytes in the periphery (3, 4, 12–16), BM lymphopenia
could reflect mobilization rather than the interruption of a
developmental pathway or cell death. For example, cells
with the characteristics of pre–B and immature B lympho-
cytes appear in mouse spleen 2 wk after immunizations
with adjuvant (3, 4, 13, 15, 17–19).
Here, we demonstrate that adjuvants suppress chemokine
CXCL12 expression in the BM and that these reductions
coincide with lymphocyte depletion and mobilization of B
cell progenitors to the blood and spleen. Recombinant
TNF
 
 
 
 alone reduces BM CXCL12, and in TNF
 
 
 
-deficient
mice, adjuvant-induced suppression of BM CXCL12 is
mitigated, BM lymphopenia is much reduced, and mobili-
zation of developing B cells is absent. Adjuvant effects on
BM are largely mimicked by pertussis toxin (PTX), which
uncouples most chemokine receptor signaling (20).
Inflammation redirects immunocyte production in BM
to favor granulopoiesis. This redirection is an unrecognized
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inflammatory response to microbial infection and a novel
pathway for the regulation of B lymphopoiesis.
 
Materials and Methods
 
Mice.
 
Female C57BL/6 (BL/6, CD45.2), B6.SJL-Ptprca/
BoAiTac (B6.SJL, CD45.1), B6.129SF2, TNF
 
 
 
 
 
/
 
 
 
 (21), and
TNF receptor I– and II–deficient (TNFR
 
 
 
/
 
 
 
) mice (22) were
obtained from the Jackson Laboratories or Taconic Farms. Mice
were housed under specific pathogen-free conditions at the Duke
University Animal Care Facility and given sterile bedding, water,
and food. Mice used in these experiments were 6–18 wk old.
 
Antigens, Adjuvants, and Cytokines.
 
Mice were immunized
with single, i.p. injections of 20 or 100 
 
 
 
g (4-hydroxy-3-nitrophe-
nyl)acetyl-chicken 
 
 
 
 globulin (NP-CGG) in alum or IFA (Sigma-
Aldrich; reference 23). NP-CGG contained 10 or 12 mol NP/mol
CGG. NP-CGG was emulsified in IFA or precipitated with alum.
Some mice were immunized with SRBCs (Duke University Farm)
in PBS or injected with 0.2 ml alum or IFA alone. LPS (
 
Escherichia
coli
 
 O127:B8; Sigma-Aldrich) was resuspended in sterile PBS, and
mice were injected i.p. with 75 
 
 
 
g LPS. Mouse rTNF
 
 
 
, rIL-1
 
 
 
,
rIL-6, and rIFN
 
 
 
 were purchased from R&D Systems. Pharmaco-
logic doses for each cytokine were confirmed by serial titrations
(0.3–3.0 
 
 
 
g/mouse). Single doses of 1 
 
 
 
g rTNF
 
 
 
, rIL-1
 
 
 
, or
1,000 U rIFN
 
 
 
 in 300 
 
 
 
l PBS were given i.v.; these doses did not
produce obvious morbidity. PTX and PTX B oligomer were pur-
chased from List Biological Laboratories.
 
Antibodies.
 
FITC-, PE-, biotin-, or allophycocyanin-conju-
gated mAb for mouse B220, Gr-1, CD3, IgM, CD4, CD8, and
CD11c were purchased from BD Biosciences. PE-Cy5–conju-
gated mAb for mouse CD4, CD8, TER-119, Gr-1, CD11b, and
FITC-conjugated anti-CD45.1 and anti-CD45.2 mAb were pur-
chased from eBioscience. Streptavidin (SA)-allophycocyanin (BD
Biosciences) and SA-Texas red (Calbiochem-Novabiochem)
identified biotinylated mAb. The 493 mAb (24) binds the fetal
stem cell antigen, AA4 (C1qRp/CD93; references 25–27), and
was purified from cloned hybridoma cells.
 
Flow Cytometry.
 
Mice were killed after injection/immuniza-
tion, and cells were harvested from spleen, femur, tibia, and
blood. RBCs were lysed in ammonium chloride buffer (23) be-
fore immunolabeling. Typically, 
 
 
 
10
 
6
 
 nucleated cells were sus-
pended in 50–100 
 
 
 
l of staining buffer (HBSS with 2% FCS and
combinations of labeled mAb) and incubated on ice for 20 min.
7-Aminoactinomycin D (Molecular Probes) was included to
identify dead cells. Labeled cells were analyzed/sorted in a FACS-
Calibur™ flow cytometer (488 nm argon laser; 633 nm helium
neon laser) or a FACStarPlus™
 
 
 
flow cytometer (488 nm argon la-
ser; 599 nm dye laser) with the OmniComp option. Cytometry
data were analyzed with FlowJo software (Treestar Inc.).
 
B Cell Colony Forming Unit Assay.
 
B cell progenitors were
enumerated as pre–B cell CFU (CFU-B; reference 6). In brief,
10
 
5
 
 BM cells or 5 
 
 
 
 10
 
5
 
 splenocytes were mixed with 1 ml
IMDM containing 1% methylcellulose, 30% FCS, 0.1 mM
2-mercaptoethanol, 2 mM glutamine, and 20 ng/ml IL-7. Sus-
pended cells were plated in 35-mm dishes and cultured at 37
 
 
 
C
for 7 d. Colonies with B cell morphology were identified and
counted by microscope.
 
Adoptive Cell Transfer.
 
3 
 
 
 
 10
 
7
 
 BM cells from B6.SJL
(CD45.1) mice were injected i.v. into BL/6 (CD45.2) recipients
immunized 3 d earlier. 1 d after transfer, femoral BM cells and
splenocytes were harvested and stained with FITC-conjugated
anti-CD45.1 and biotinylated anti-B220 mAb, followed by SA–
 
Texas red. Labeled, donor-derived cells were enumerated by flow
cytometry to determine homing and migration efficiencies. BM
cells from TNFR
 
 
 
/
 
 
 
 (CD45.2) mice were transferred into naive
or immunized B6.SJL (CD45.1) mice. Donor B cells recovered
from the BM and spleen of recipients were distinguished from
host cells by anti-CD45.2 mAb.
 
RT-PCR.
 
Total RNA was extracted from BM using RN-
easy-kits (QIAGEN); 1 
 
 
 
g RNA was reverse transcribed for 1 h
at 42
 
 
 
C (Superscript II reverse transcriptase; Invitrogen). PCR
was performed on serial dilutions of cDNA using Taq polymerase
(Takara Bio Inc.). PCR primers used were as follows: HPRT,
forward, 5
 
 
 
-GCTGGTGAAAAGGACCTCT-3
 
 
 
, reverse, 5
 
 
 
-
CACAGGACTAGAACACCTGC-3
 
 
 
; CXCL12, forward, 5
 
 
 
-
GTCCTCTTGCTGTCCAGCTC-3
 
 
 
, reverse, 5
 
 
 
-TAATTTC-
GGGTCAATGCACA-3
 
 
 
; and CXCL12
 
 
 
, reverse, 5
 
 
 
-TGG-
GCTGTTGTGCTTACTTG-3
 
 
 
; CXCL12
 
 
 
, reverse, 5
 
 
 
-CCT-
CTCACATCTTGAGCCTCTT-3
 
 
 
. Amplification parameters
were as follows: initial denaturation at 94
 
 
 
C for 5 min, 25–32
amplification rounds consisting of denaturation at 94
 
 
 
C for 30 s,
annealing at optimal temperatures, and extension for 60 s at 72
 
 
 
C.
A final extension round of 72
 
 
 
C for 10 min ended each amplifica-
tion. Optimal annealing temperatures were as follows: 52
 
 
 
C for
HPRT and CXCL12, and 60
 
 
 
C for CXCL12
 
 
 
 and -
 
 
 
. PCR
products were electrophoresed over 2% agarose gels containing
ethidium bromide.
 
Preparation of BM Plasma and CXCL12 ELISA.
 
BM plasma
was prepared by flushing both femurs and tibia with 500 
 
 
 
l of
cold PBS into Eppendorf-type centrifuge tubes. Cells/debris
were removed by centrifugation at 3,000 
 
g
 
 for 10 min at 4
 
 
 
C;
BM plasma was stored at 
 
 
 
20
 
 
 
C.
CXCL12 protein concentrations were determined by ELISA.
In brief, 96-well plates (BD Falcon™; BD Biosciences) were
coated overnight with anti-CXCL12 mAb 79018 (R&D Sys-
tems) (2 
 
 
 
g/ml in 0.1 M carbonate buffer) at 4
 
 
 
C. Serially diluted
BM plasma samples were loaded, incubated overnight at 4
 
 
 
C, and
washed with PBS containing 0.1% Tween 20. Bound CXCL12
was detected by biotinylated anti-CXCL12
 
 
 
 mAb (BAF310;
R&D Systems) and horseradish peroxidase–SA (Southern Bio-
technology Associates, Inc.). Horseradish peroxidase activity was
visualized using a tetramethylbenzidine peroxidase substrate kit
(Bio-Rad Laboratories). CXCL12 concentrations were deter-
mined from purified CXCL12 standards (PeproTech).
 
Online Supplemental Material.
 
Table S1 summarizes the effects
of several inflammatory agents on thymocytes. Fig. S1 illustrates
reductions of CXCL12 message in BM by adjuvant and TNF
 
 
 
.
Fig. S2 shows that the PTX B oligomer has no effect on BM. Fig.
S3 compares the ability of antigens/adjuvants to induce BM lym-
phopenia. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20031104/DC1.
 
Results
 
Adjuvants Deplete BM Lymphocytes and Induce the Appear-
ance of Developing B Cells in the Periphery.
 
Immunization
with NP-CGG/IFA reduces the numbers of developing
(CD93
 
 
 
B220
 
lo
 
) and mature (CD93
 
 
 
B220
 
hi
 
; reference 24)
BM B cells (Fig. 1 A); losses are evident 3 d after immuni-
zation, with maximal reductions coming on days 4–6
(CD93
 
 
 
B220
 
lo
 
 B cells, four- to fivefold reductions;
CD93
 
 
 
B220
 
hi
 
 B cells, sevenfold) (Fig. 1 B). Thereafter, de-
veloping and mature B cell numbers in the BM return to
normal levels (Fig. 1 B). Both B cell populations decline at 
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similar rates, but losses of CD93
 
 
 
B220
 
hi
 
 cells are signifi-
cantly (P 
 
  
 
0.05) greater and more sustained than that of
CD93
 
 
 
B220
 
lo
 
 cells. Similar kinetics of loss and recovery
are also observed for BM T cells (Table I and unpublished
data), indicating that all BM lymphocyte populations are
sensitive to adjuvant-induced depletion.
In contrast, BM granulocyte numbers, especially less ma-
ture Gr-1
 
int
 
 cells (28), increase after immunization (Fig. 1,
C and D). Gr-1
 
 
 
 cell numbers significantly increase 1 wk
after immunization, reach maximal levels on day 16 (naive,
8.8 
 
 
 
 1.8 
 
 
 
 10
 
6
 
; and day 16, 20.4 
 
 
 
 3.5 
 
 
 
 10
 
6
 
, P 
 
  
 
0.01),
and then gradually fall to normal levels (Fig. 1 D).
To determine if adjuvant-induced depletion of BM
lymphocytes includes cell mobilization, we enumerated
CD93
 
 
 
B220
 
lo
 
 blood cells after immunization. CD93
 
 
 
B220
 
lo
 
 blood cell numbers increased soon after immuniza-
tion (Fig. 2, A and B), with a peak at day 3 (naive, 5.3 
 
 
 
1.8 
 
  103 cells/ml; and day 3, 14.7   3.7   103 cells/ml,
P    0.05). Developing B cell numbers in blood re-
turned to normal levels (Fig. 2 B, day 8, 3.4   0.7  
103 cells/ml, P   0.42; day 12, 7.4   1.2   103 cells/
ml, P   0.08; and day 16, 8.9   2.3   103 cells/ml,
P   0.10).
Immunization also increased the fraction of IgM  cells
among CD93 B220lo blood cells. In naive animals, 80–
90% of CD93 B220lo blood cells are IgMhi, transitional B
cells (Fig. 2 C; reference 29). 3 d after immunization, the
IgM  fraction of CD93 B220lo blood cells increased to
 45% (Fig. 2 C); adjuvants increase the numbers of
CD93 B220lo blood cells by expanding the IgM 
compartment. As reported previously (3, 13, 17, 18),
CD93 B220lo IgM  cell numbers in the spleen also in-
creased after immunization (Fig. 2 A). Transient, nonsig-
nificant (P    0.06) increases immediately followed the
peak of CD93 B220loIgM  cells in blood, but larger and
sustained increases began at day 8 (naive, 1.6   0.1   105;
day 8, 3.6   0.6   105, P   0.05) and continued until day
16 (Fig. 2 B, 11.0   0.6   105, P   0.01). In both blood
and spleen, CD93 B220loIgM  cells did not express
CD11b, CD11c, CD8, or TER-119 (unpublished data).
Figure 1. Immunization depletes BM B cells but increases
BM granulocyte numbers. BL/6 mice were immunized with
NP-CGG/IFA. Lymphocytes and granulocytes from femur
and tibia were analyzed by flow cytometry; representative
FACS® profiles of BM cells (A, B220 and CD93; C, B220 and
Gr-1) 3 or 4 d after immunization. Percentages of gated
CD93 B220lo, CD93 B220hi, and Gr-1 B220  cells are
given. 3 d after immunization, CD93 B220lo and CD93 B220hi
cell numbers fall in the BM (A), whereas Gr-1 B220  cell
numbers change little (C). Dynamics of BM B cell (B) or
granulocyte (D) populations indicate that B lymphopenia
persists for  12 d (B), whereas granulocyte numbers increase
(D). Points represent mean    SEM of CD93 B220lo (  ),
CD93 B220hi ( ), and Gr-1 B220  cells ( ). Asterisks indicate
significant differences from controls: *, P   0.05; **, P   0.01. 
Table I. Effects of Various Inflammatory Agents on BM Cell Populations
Bone marrow na Total B220lo B220hi Gr-1 CD3
PBS 19 216   9.7b 43.0   4.2 31.7   3.2 88.1   4.0 8.1   1.7
NP-CGG/IFA 5 264   11.5c 13.7   0.7c 7.9   0.2c 184   9.6c 1.2   0.2c
TNF  15 178.4   16.3d 23.2   2.4c 13.1   1.7c 108.2   10.6 1.3   0.1c
IL-1  7 218   7.5 33.7   3.6 24.6   1.5 116.6   5.7c 4.5   0.7
IL-6 5 199   17.2 45.3   1.8 22.2   1.8 76.1   2.0 3.9   0.3d
IFN  6 229   14.8 44.0   7.7 35.4   1.7 75.6   7.7 11.9   2.4
TNF  + IL-1  4 281   17.3c 13.2   3.2c 8.5   2.2c 218.3   17.4c 1.3   0.3c
PTX 4 148   9.3c 6.9   0.5c 2.2   0.1c 99.6   7.5 1.3   0.1c
aTotal number of mice from multiple (two to eight) experiments (TNF  and IL-1  is a single experiment).
bMean   SEM ( 106) number of cells recovered from the femurs of individual mice 6 d after treatment.
cP   0.01.
dP   0.05.Inflammation Controls B Lymphopoiesis 50
To determine whether these CD93 B220lo IgM  cells
were B lineage progenitors, we enumerated CFU-B in BM
and spleen after immunization. CFU-B are abundant in the
BM of naive mice (12.9   1.0   103 cells/femur), but rare in
the spleen (Fig. 3, A and B, 0.2   0.1   103 cells/spleen). In
4 d, adjuvants decrease the numbers of BM CFU-B to  25%
of controls (P   0.01); these reductions are sustained until
day 8 (Fig. 3 A). Significant increases in splenic CFU-B occur
8 d after immunization (0.5   0.1   103 cells/spleen, P  
0.05), with CFU-B numbers peaking at day 12 (4.3   1.3  
103 cells/spleen, P   0.01) and declining thereafter (Fig. 3 B).
TNF  Mimics Inflammation’s Effects on BM. To deter-
mine if a single proinflammatory cytokine could reproduce
adjuvant’s effects on BM, we administered rTNF , rIL-1 ,
rIL-6, or rIFN  to BL/6 mice and followed changes in
lymphocyte and granulocyte numbers.
Of these cytokines, only TNF  recapitulated the cell
mobilizations induced by adjuvant (Table I). 6 d after injec-
tion, TNF  reduced BM CD93 B220lo, CD93 B220hi,
and CD3  cell numbers to 54, 41, and 16% of controls, re-
spectively. In addition, TNF  modestly increased BM gran-
ulocyte numbers (123% of controls, P   0.07). These effects
are similar to those of adjuvants, albeit less profound and
persistent. For example, adjuvant reduced CD93 B220lo,
CD93 B220hi B cells in the BM by five- and sevenfold, re-
spectively, whereas TNF  reduced CD93 B220lo and
CD93 B220hi BM cells two- and threefold (Fig. 1 and Ta-
ble I). In contrast to their strong effects on BM, both adju-
vants and TNF  induced only modest and transient changes
in the thymus (Table S1, available at http://www.jem.org/
cgi/content/full/jem.20031104/DC1).
Neither IL-6 nor IFN  significantly altered CD93 
B220lo or CD93 B220hi BM cell numbers, nor did they
change granulocyte numbers (Table I). IL-1  lowered
B220  BM cell numbers nonsignificantly ( 80% of con-
trols, P   0.11) but significantly expanded granulocytes
(Table I, 132% of controls, P   0.01).
Noting that TNF  primarily reduced BM lymphocyte
numbers, whereas IL-1  expanded the BM granulocyte
compartment, we tested whether these cytokines synergize
by injecting 0.5  g TNF  and 0.5  g IL-1  singly or in
combination. Synergy was obvious; TNF  and IL-1  to-
gether reduced B220  ( 30% of controls, P   0.01) and
CD3  (16% of controls, P   0.01) BM cell numbers more
effectively than higher doses either cytokine alone (Table
I). Potentiation was also apparent in significantly larger in-
creases in the BM Gr-1  populations (Table I, 250% of
controls, P   0.01). In combination, TNF  and IL-1 
fully recapitulate adjuvant-induced change in BM lympho-
cyte and granulocyte populations.
TNF  Mobilizes B Cell Progenitors from the BM. To de-
termine if TNF  mobilized BM lymphocytes, we enumer-
Figure 2. Appearance of CD93 B220lo cells
in the periphery after immunization.
CD93 B220lo B cells in the blood (BL) and
spleen (SPL) of immunized BL/6 mice at days
3–16 were characterized and enumerated by
flow cytometry. (A) Representative FACS®
profiles of CD93 B220lo and CD93 B220hi
cells in BL and SPL. Percentages of gated
CD93 B220lo cells are indicated. (B) Kinetics
of CD93 B220lo cell numbers in BL and SPL
after immunization. Asterisks indicate signifi-
cant differences from controls: *, P   0.05;
**, P   0.01. (C) Surface IgM expression by
CD93 B220lo cells in BL and SPL. Shaded areas,
solid lines, and dashed lines represent surface
IgM expression by CD93 B220lo, CD93 
B220hi, and B220  cells, respectively. Percent-
ages of IgM  cells in CD93 B220lo cell gates
are shown.
Figure 3. Immunization in-
creases splenic CFU-B numbers.
BL/6 mice were immunized
with 5   108 SRBCs in 200  l
IFA. 4–16 d later, spleen and
BM cells were harvested, and
CFU-B were enumerated after
culture for 7 d. (A) Femoral BM
CFU-B. (B) Splenic CFU-B
numbers after immunization.
Asterisks indicate significant dif-
ferences from controls: *, P  
0.05; **, P   0.01. Ueda et al. 51
ated CD93 B220lo cells in the periphery after injecting
rTNF . 3 d after injection, CD93 B220lo cells increased
two- to threefold in the blood (P   0.05) and spleen (P  
0.05) (Fig. 4 A). In control mice,  15% of CD93 B220lo
cells in blood and spleen were IgM ; after TNF  treat-
ment, IgM  cells comprised 55–65% of both CD93 
B220lo populations (Fig. 4 B). Thus, rTNF  mobilizes
CD93 B220loIgM  cells to peripheral tissues.
If TNF  plays a principal role in adjuvant-induced BM
lymphopenia, lymphocyte mobilization should be reduced
or absent in TNF knockout animals. We immunized
TNF  /  mice and congenic controls and followed
changes in CD93 B220lo and CD93 B220hi cell numbers
in BM, blood, and spleen. 4 d after immunization, sub-
stantial losses of CD93 B220lo (27% of controls) and
CD93 B220hi (7% of controls) BM cells were evident in
B6.129SF2 mice. In contrast, immunization of TNF  / 
mice resulted in approximately twofold reductions of
CD93 B220lo (65% of controls) and CD93 B220hi (42% of
controls) cells (Fig. 5 A).
Although BM lymphopenia was reduced, mobilization
of CD93 B220lo cells was not detectable in TNF  knock-
outs. 4 d after immunization, CD93 B220lo cells increased
two- to threefold in the blood (naive, 5.8   3.9   103
cells/ml; day 4, 18.7   0.5   103 cells/ml; P   0.01) and
spleen (naive, 1.1   0.6   105 cells/spleen; day 4, 2.5  
0.7   105 cells/spleen; P   0.05) of TNF  sufficient con-
trols (Fig. 5 B). In contrast, CD93 B220lo cell numbers did
not increase in the blood (naive, 4.7   2.6   103 cells/ml;
day 4, 3.2   3.1   103 cells/ml; P   0.44) or spleen (na-
ive, 0.9   0.5   105 cells/spleen; day 4, 0.5   0.2   105
cells/spleen; P   0.15) of immunized TNF /  mice (Fig. 5
B). Thus, TNF  is a principal component of adjuvant-
induced BM lymphopenia and mobilization.
Figure 4. TNF  mobilizes CD93 B220loIgM  cells. (A)
Representative FACS® profiles of blood (BL) and spleen (SPL)
cells from PBS- and TNF -injected mice. Percentages indicate
CD93 B220lo cells in the lymphocyte gate. (B) IgM expres-
sion by CD93 B220lo B cells from BL and SPL. Shaded areas,
solid lines, and dashed lines represent surface IgM expression
by CD93 B220lo, CD93 B220hi, and B220  cells, respec-
tively. Numbers indicate percentages of IgM  cells in
CD93 B220lo cell gates.
Figure 5. Adjuvant-induced BM lymphopenia and B cell mobili-
zation in TNF  /  mice. TNF  /  mice and congenic controls
were immunized with NP-CGG/IFA. 3 d after immunization, B
cells in BM and spleen (SPL) were analyzed by flow cytometry.
(A) Adjuvant-induced BM lymphopenia is mitigated in TNF  / 
mice. Bars represent mean   SD of B220lo and B220hi cell numbers
from two femurs of naive (unshaded) or immunized (shaded)
mice. Asterisks indicate significant differences from controls: *,
P   0.05; **, P   0.01. (B) Mobilization of CD93 B220lo cells is
absent in TNF /  mice. Representative FACS® profiles for
CD93 B220lo and CD93 B220hi cells in the blood (BL) and SPL
of naive and immunized mice are shown. Percentages of BL and
SPL CD93 B220lo lymphocytes (CD11c-, Gr-1–, Mac-1–, CD8-,
and TER-119–negative) are shown.Inflammation Controls B Lymphopoiesis 52
Immunization and TNF  Reduce CXCL12 in the BM.
CXCL12 and its receptor, CXCR4, are crucial for the
homing of hematopoietic progenitor cells (30–33), and in-
terruption of CXCL12/CXCR4 interaction mobilizes BM
stem cells (34, 35). Could inflammation/TNF  mobilize
BM B cells by reducing BM CXCL12/CXCR4 expression
and/or signaling? We measured CXCL12 message in BM
by semi-quantitative RT-PCR. In naive mice, CXCL12
mRNA was detected in unsorted BM cells, but absent or
much reduced in the B cell, T cell, and granulocyte com-
partments (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20031104/DC1), consistent with the pro-
duction of CXCL12 by nonhematopoietic stromal cells
(36). 3 d after immunization or i.v. TNF , levels of
CXCL12  and -  mRNA (36) fell twofold in BM,
whereas HPRT mRNA levels remained constant (Fig. S1).
CXCL12 protein in BM plasma also declined after im-
munization or TNF  injection. In control mice, the aver-
age concentration of CXCL12 in BM plasma was 14.0  
2.0 ng/ml. 3 d after immunization, CXCL12 protein levels
dropped sixfold to 2.3   2.0 ng/ml (P   0.01; Fig. 6 A).
These losses were specific, as total protein levels in the BM
plasma of control and immunized mice were identical (Fig.
6 A). After immunization, CXCL12 returned to near nor-
mal levels by day 8 (Fig. 6 B). This pattern of decreased
CXCL12 expression follows the course of BM lymphocyte
loss and recovery after immunization (Fig. 1 B).
TNF  also inhibited BM CXCL12 protein production,
but less profoundly than adjuvant. 3 d after TNF , BM
CXCL12 levels fell to 8.3   1.6 ng/ml (P   0.05; Fig. 6
A). Adjuvant-induced reductions of CXCL12 protein are
greater than reductions in mRNA, whereas TNF  induces
comparable reductions in both (Fig. 6 and Fig. S1). We in-
terpret this difference to reflect distinct regulatory mecha-
nisms (35, 37–39).
Figure 6. Adjuvants and TNF  suppress BM CXCL12. (A) Adjuvants
and TNF  reduce BM CXCL12 protein, but do not alter total protein
levels. Bars represent mean   SD protein concentrations. (B) CXCL12
protein levels in BM plasma of BL/6 mice after immunization. Points
represent mean   SD CXCL12 concentrations. Asterisks indicate significant
differences from controls: *, P   0.05; **, P   0.01. (C) Adjuvant-induced
suppression of BM CXCL12 is mitigated in TNF  /  mice. 3 d after
immunization, CXCL12 protein concentrations in BM plasma of TNF  / 
and control mice were determined. Experimental groups are as follows:
naive TNF / , untreated B6.129SF2; NP-CGG/IFA TNF / , immu-
nized B6.129SF2; naive TNF / , untreated TNF  / ; and NP-CGG/
IFA TNF / , immunized TNF / .
Figure 7. Transferred BM B cells do not home efficiently in immu-
nized recipients. (A) BM cells from naive B6.SJL (CD45.1) animals were
transferred into naive or immunized, congenic (CD45.2) recipients. 1 d
after transfer, donor B220lo and B220hi cells in the BM and SPL of recipients
were enumerated by flow cytometry. (B) Homing of TNFR /  BM B
cells in immunized recipients is impaired. BM cells from naive, TNFR / 
(CD45.2) mice were transferred into naive and immunized (CD45.1)
recipients. 1 d after transfer, donor B cells in the BM and SPL of recipients
were enumerated. Bars indicate mean   SD numbers of CD45.2 B cells
recovered from naive (unshaded) and immunized (shaded) recipients. Aster-
isks indicate significant differences from controls: *, P   0.05; **, P   0.01.Ueda et al. 53
CXCL12 Reduction in TNF  /  Mice. In naive
B6.129SF2 mice, the average concentration of CXCL12
protein in BM plasma (Fig. 6 C, 19   1.9 ng/ml) is similar
to BL/6 mice (Fig. 6 A); 4 d after immunization, BM
CXCL12 concentrations fell below detectable levels (Fig. 6
C,   1 ng/ml). In contrast, immunization of TNF  / 
mice reduces BM CXCL12 levels by  50% (Fig. 6 C, na-
ive, 21   1.1 ng/ml; immunized, 11   3.4 ng/ml). These
reductions were specific, as total BM plasma protein re-
mained constant in all groups (Fig. 6 C).
Homing to BM Is Reduced in Immunized Mice. If adju-
vants mobilize BM lymphocytes by reducing CXCL12,
normal cells should be unable to colonize the BM of im-
munized mice. To test this prediction, BM cells from na-
ive, CD45.1 donors were transferred into naive or immu-
nized CD45.2 recipients; 24 h later, CD45.1 B cells in the
BM and spleen were enumerated by flow cytometry.
CD45.1 donor B cells readily entered the BM of naive
recipients. We typically recovered 2.0   0.4   105
CD45.1 B220lo cells and 0.4   0.2   105 CD45.1 B220hi
cells from each femur and tibia from naive hosts (Fig. 7 A).
In immunized recipients, we only recovered 0.6   0.3  
105 CD45.1 B220lo cells (30% of controls, P   0.01) and
0.03   0.02   105 CD45.1 B220hi cells (7% of controls,
P   0.01). In contrast, equivalent numbers of CD45.1 
B220hi cells were present in the spleens of both naive
(3.1   1.7   105) and immunized hosts (3.7   2.2   105),
and more CD45.1 B220lo cells were consistently recovered
from the spleens of immunized than from naive recipients
(Fig. 7 A, 14.7   2.7   105 vs. 7.0   2.9   105; P  
0.01).
To exclude the possibility that defective BM homing in
immunized recipients was due to TNF -mediated change
in the transferred cells, we transferred 1.5   107 BM cells
from TNFR /  mice (CD45.2) into naive or immunized
B6.SJL (CD45.1) hosts (Fig. 7 B). Average recoveries from
the BM of naive recipients were 1.4   0.3   105
CD45.2 B220lo and 0.4   0.1    105 CD45.2 B220hi
TNFR-deficient cells. However, only 0.6   0.3   105
CD45.2 B220lo cells (43% of controls, P   0.05) and
0.03   0.02   105 CD45.2 B220hi TNFR-deficient cells
(10% of controls, P   0.01) were recovered from the BM
of immunized recipients.
PTX Depletes BM Lymphocytes and Mobilizes Developing B
Cells. In association with reductions in CXCL12, adju-
vant mobilizes BM lymphocytes and increases granulocyte
numbers (Figs. 1 and 6), with little effect on thymocytes
(Table S1). If CXCL12 reductions cause these changes, a
blockade of CXCL12 signals must produce similar results.
We injected BL/6 mice with PTX, an inhibitor of many
chemokine receptors, including the CXCL12 receptor,
CXCR4 (20), and followed its effects on BM and thymus.
3 d after injecting PTX, CD93 B220lo and CD93 B220hi
BM cell numbers fell significantly and remained suppressed
until day 12. B cell numbers began to recover 12–18 d after
PTX treatment, reaching normal levels by day 24 (Fig. 8
A). PTX also lowered CD3  BM cell numbers (Table I)
with similar kinetics (unpublished data). These effects were
dependent on the ribosyltransferase activity of PTX, as the
enzymatically inactive PTX B oligomer had no effect on
BM (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20031104/DC1). PTX had little effect
on thymocyte populations (Table S1).
PTX did not elicit losses of BM granulocytes. Instead,
granulocyte numbers in the BM began to increase as soon
as 6 d after PTX treatment with peak numbers at day 18.
Figure 8. PTX elicits BM lymphopenia and mobilizes
CD93 B220loIgM  cells. BM, blood (BL), and spleen (SPL)
cells were harvested from BL/6 mice 0–24 d after injection of
300–500 ng PTX and analyzed by flow cytometry. (A) Dynamics
of BM B cell subsets (left) and granulocytes (right). Points
represent mean   SEM numbers of B220lo ( ), B220hi ( ),
and Gr-1  (  ) cells from two femurs. (B) Appearance of
CD93 B220loIgM  cells in the periphery after PTX treat-
ment. FACS® profiles of CD93 B220lo and CD93 B220lo
cells from BL and SPL in PBS- and PTX-treated mice are
shown. Percentages of cells in the CD93 B220lo gate are indi-
cated. (C) PTX elicits populations of CD93 B220loIgM  cells
in BL and SPL. Representative FACS® profiles of surface IgM
expression by CD93 B220lo cells. Shaded areas, solid lines,
and dashed lines represent surface IgM expression by
CD93 B220lo, CD93 B220hi, and B220  cells, respectively.
Percentages of IgM  cells in CD93 B220lo cell gates are shown.Inflammation Controls B Lymphopoiesis 54
Later, BM granulocyte numbers began a return to basal
levels (Fig. 8 A).
PTX also mobilized CD93 B220lo BM cells; 3 d after
injecting PTX, CD93 B220lo cell numbers were signifi-
cantly higher in blood (P   0.01) and spleen (Fig. 8 B, P  
0.01). The majority of these peripheral CD93 B220lo cells
(blood, 56%; spleen, 66%) were surface IgM  (Fig. 8 C).
Discussion
Infections and adjuvants can produce BM lymphopenia
(1–3, 9). BM B (CD93 B220lo and CD93 B220hi) and T
lymphocyte numbers fall significantly in the first week after
immunization with adjuvant, but both compartments begin
recoveries in the second week and approach normal levels
in the third (3). Recovery in the BM is coincident with the
appearance of splenic CD93 B220lo cells that express
RAG1/2 and  5 (3). In contrast, BM granulocyte numbers
do not fall but increase after immunization (3). These ob-
servations suggest that inflammation affects BM hemato-
poiesis to favor granulocyte production. However, the
mechanisms responsible for inflammation-induced changes
in the BM are unknown.
Here, we show that adjuvants suppress BM CXCL12 and
mobilize functional B cell progenitors (B220loCD93 IgM 
cells and CFU-B) into the periphery. Both phenomena can
be mediated by rTNF , and both are reduced or absent in
TNF  /  mice. A blockade of G i-dependent signaling by
PTX recapitulates these effects in the absence of an overt in-
flammatory response. We conclude that inflammation acts
via TNF  and CXCL12 to reduce the BM lymphocyte
compartments in preparation for expanded granulocyte pro-
duction. This model outlines a novel inflammatory response
and predicts that innate immune responses are physiologic
regulators of central hematopoiesis.
Regulation of B Lymphopoiesis during Inflammation. Adju-
vants, LPS, and gram-negative bacteria, but not noninflam-
matory antigens such as SRBCs (references 3, 4; Fig.
S3, available at http://www.jem.org/cgi/content/full/jem.
20031104/DC1) deplete all BM lymphocyte compart-
ments equally (Fig. 1 and Table I; references 3, 4). The
mechanism of depletion has been unclear, but cytokine-
driven apoptosis was a favored candidate (7–10). Develop-
ing B cells are sensitive to apoptotic signals (7) and severe
viral infection or high doses of IFN /  suppress B lym-
phopoiesis by apoptosis (8–10). However, this apoptosis
likely represents a pathologic or pharmacologic response
(8). In our hands, adjuvant-induced depletions of lympho-
cytes are not biased for developmentally immature com-
partments (Fig. 1), are restricted to the BM (Table S1), and
unassociated with obvious morbidity or pathology.
Although we cannot rule out an apoptotic component,
adjuvant-induced BM lymphopenia is coincident with a
massive mobilization of BM lymphocytes that results in the
appearance of CD93 B220loIgM  cells in the blood and
spleen (Fig. 2). These CD93 B220loIgM  cell populations
include functional CFU-B (Fig. 3), providing an explana-
tion the findings that the RAG  splenocytes elicited by ad-
juvant are not mature lymphocytes and require functional
BM (4, 19).
TNF  Mobilizes BM Lymphocytes. Adjuvant’s effects
on BM could be fully reproduced by two proinflammatory
cytokines, TNF  and IL-1  (Table I). TNF  significantly
decreases BM lymphocyte numbers (Table I), mobilizes
B220loCD93 IgM  cells (Fig. 4), and modestly expands
the BM granulocyte compartment (Table I). A central role
for TNF  in adjuvant-induced loss of BM lymphocytes
was confirmed in TNF  /  mice (Fig. 5) that exhibited
much reduced BM lymphopenia and no mobilization of
CD93 B220lo cells.
However, residual losses of BM B cells in immunized
TNF  /  mice indicate that inflammation does not act via
TNF  only. IL-1  elicited a nonsignificant BM lym-
phopenia but greatly expanded granulocyte numbers (Ta-
ble I). The effects of IL-1 in vivo are similar to those ob-
served in vitro by Dorshkind (6) and complement TNF .
Suboptimal doses of TNF  and IL-1  synergize to act on
BM as profoundly as complex inflamogens (Table I and
Fig. S3). Thus, the primary effect of TNF  appears to be
the mobilization of BM lymphocytes, whereas IL-1  pro-
motes granulocytic expansion. A similar potentiation has
been observed in rats (40).
Adjuvants and TNF  Suppress BM CXCL12. CXCL12
attracts many hematopoietic cells (34, 41, 42), including
progenitor B cells, and is important for their survival, dif-
ferentiation, and localization (33). Both adjuvants and
TNF  reduce CXCL12 in the BM, and these reductions
mirror lymphocyte mobilization (Fig. 6, A and B). Adju-
vant-induced reductions of CXCL12 in TNF  /  mice
were substantially less than in controls (Fig. 6 C) and con-
sistent with reduced BM lymphopenia and lack of
CD93 B220lo cell mobilization (Fig. 5). Inflammation mo-
bilizes BM lymphocytes by suppressing CXCL12 expres-
sion. Although adjuvants lower CXCL12 mRNA approxi-
mately threefold, CXCL12 protein falls to  20% of
controls; rTNF  reduces BM CXCL12 mRNA and pro-
tein to  50% of control levels (Fig. 6 and Fig. S1). The
contrasting ranges of CXCL12 message and protein levels
in the BM suggest that inflammation regulates chemokine
expression transcriptionally and posttranslationally.
Consistent with this idea, Fedyk et al. (37) showed that
TNF  modestly suppressed CXCL12 transcription in der-
mal fibroblasts, whereas Petit et al. (35) found that granulo-
cytes substantially lowered CXCL12 levels by elastase-
driven proteolysis. Other enzymes secreted by granulocytes
(e.g., matrix metalloproteinases and cathepsin G) also inac-
tivate CXCL12 (38, 39).
Inflammation Alters the BM to Prevent Cell Homing.
B220lo and B220hi BM cells from naive donors inefficiently
home in immunized recipients (Fig. 7). Reduced homing
efficiency is not due to TNF-mediated change in the trans-
ferred cells, as TNFR /  cells do not enter the BM of im-
munized recipients (Fig. 7 B). We conclude that inflamma-
tion modifies the BM by reducing CXCL12 sufficiently toUeda et al. 55
no longer attract and/or retain lymphocytes. The observa-
tion that PTX, a G i poison that inhibits most chemokine
signaling (20), mimics inflammation’s effects on BM and
mobilizes CD93 B220loIgM  cells (Fig. 8 and Table I) is
consistent with this model, but is not a proof.
Retention of BM Granulocytes. In vitro, granulocytes dis-
play strong, G i-dependent chemotaxis to CXCL12 (refer-
ence 43 and unpublished data). CXCL12 and CXCR4 are
crucial for both myelopoiesis and B lymphopoiesis (30, 31),
and mice reconstituted with CXCR4-deficient fetal liver
cells have increased numbers of developing granulocytes
and B cells in their blood (33). How is it that reductions of
CXCL12 or inhibition of chemokine signaling by PTX de-
pletes BM lymphocytes but not granulocytes?
One possibility is that the chemotactic sensitivities of B
cells and granulocytes to CXCL12 differ. If granulocytes
respond to significantly lower concentrations of CXCL12
( 1 ng/ml) than lymphocytes, reductions of CXCL12
would favor the retention of granulocytes in the BM. In
the absence of CXCL12/CXCR4, such selectivity would
be lost. Increased sensitivity to CXCL12 signals would also
make granulocytes relatively resistant to nonsaturating
doses of PTX.
Although early myeloid progenitors depend on
CXCL12 to enter the BM, Gr-1int and Gr-1hi granulocytes
(28) might be retained there by other chemokines. For ex-
ample, LPS induces BM stromal cells to express CCL21, a
chemokine for myeloid progenitors (44). Other myeloid
chemoattractants, CCL3 and CCL8, are expressed in BM
as well (45). In this model, granulocytes would normally
depend on CXCL12 homing/retention signals, but are
held in the BM by other chemokines during infection.
A third possibility is that G i-independent mechanisms
retain granulocytes in the BM. Although the initial local-
ization of myeloid progenitors in the BM is CXCL12 and
G i dependent (30, 31, 33), retention of developing and
mature granulocytes in the BM could be G i-independent
(46–49). These PTX-insensitive pathways could be consti-
tutive or induced by inflammation.
None of these models are mutually exclusive, and we are
in the process of testing each. However, our data show that
BM lymphocytes and granulocytes respond differently to
environmental cues that control their retention in the BM
(Figs. 1 and 8; Table I).
Lymphopoiesis and Granulopoiesis during Inflammation.
Although severe inflammation may induce apoptosis in BM
lymphocytes (9, 40), milder inflammation mobilizes BM
lymphocytes to the blood and spleen (Fig. 2) and establishes
extramedullary B lymphopoiesis (Fig. 3). Lymphocyte mo-
bilization is associated with increased numbers of Gr-1int
cells and expansion of the BM granulocyte compartment
(Fig. 1, C and D). The coordination of these changes sug-
gests a regulated, physiologic response. We propose that in-
flammatory agents elicit TNF  (and other potentiating cy-
tokines) at sites of infection, and perhaps in the BM (50),
sufficiently to suppress BM CXCL12. Initially, this sup-
pression occurs by transcriptional inhibition (reference 37
and Fig. S1), but later it occurs by proteolysis from an ex-
panded granulocyte compartment (35, 38, 39). IL-1  pro-
motes granulocytic expansion, especially in the presence of
TNF  (Table I). Reduced CXCL12 levels mobilize BM
lymphocytes, and initiate extramedullary lymphopoiesis. In
the spleen, displaced CFU-B proliferate and differentiate
into pre–B and immature B cells that express RAG1/2 and
 5 (Figs. 2 and 3; references 3, 4, 13, 16, 19).
BM granulocytes appear to expand into generative niches
abandoned by mobilized lymphocytes. Although IL-1 
promotes myelopoiesis (Table I; reference 6), its effects are
strongly potentiated by TNF -induced mobilizations. This
synergy of TNF  and IL-1  suggests that lymphopoiesis
and myelopoiesis compete in the BM. Competition for
space or resources is also implicit in pharmacologic modula-
tions of hematopoiesis (i.e., factors that promote granulo-
cyte development mobilize lymphocyte progenitors [refer-
ence 51] and vice versa [references 52, 53]).
Alternatively, it is possible that the recovery of BM lym-
phocyte compartments and increased granulocyte numbers
represents a general increase in the ability of the BM to
support hematopoiesis. This increased generative capacity
might result from the accumulation of growth resources
over the lymphopenic period.
The utility of increasing granulopoiesis in response to in-
flammation is obvious. Mature granulocytes are unable to
divide and once activated, survive only hours to days. The
ability to increase granulocyte production to replenish cells
lost in inflammatory responses would be considerably ad-
vantageous as persistent neutropenia leads to death from in-
fection (54, 55)
The advantage of extramedullary B lymphopoiesis is less
obvious. Nonetheless, it is clear that inflammation pro-
motes transient, extramedullary B lymphopoiesis. We think
it unlikely that this splenic lymphopoiesis has no physio-
logic role. The appearance of CFU-B in the spleen is well
regulated (unpublished data) and the number of pre–B and
immature B cells that arise there can comprise 10–20% of
splenic B220  cells (references 3, 4, 18; unpublished data).
Perhaps some fraction of these cells are recruited into local
humoral responses (15–17, 56)?
In conclusion, adjuvant-induced BM lymphopenia re-
flects the mobilization of lymphocytes. This mobilization is
mediated by a TNF /CXCL12 axis that intimately links
the innate and adaptive immune systems. Proinflammatory
cytokines not only act as immune effectors and organizers
of lymphoid tissue but also direct BM hematopoiesis.
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